{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:24:21Z","timestamp":1787181861672,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002241","name":"JST","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.biopha.2026.119793","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:58:53Z","timestamp":1785322733000},"page":"119793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Mirabody\u2013IR700: A novel EGFR-targeting platform for photoimmunotherapy"],"prefix":"10.1016","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5307-4681","authenticated-orcid":false,"given":"Citra R.A.P.","family":"Palangka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motofumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119793_bib1","first-page":"68","article-title":"Near-infrared photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research","volume":"8","author":"Allen","year":"2025","journal-title":"Antib. Ther."},{"key":"10.1016\/j.biopha.2026.119793_bib2","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/nm.2554","article-title":"Cancer cell\u2013selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules","volume":"17","author":"Mitsunaga","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119793_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1485242","article-title":"Near-infrared photoimmunotherapy in cancer treatment: a bibliometric and visual analysis","volume":"15","author":"Tian","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119793_bib4","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1515\/nanoph-2021-0119","article-title":"Near infrared photoimmunotherapy of cancer; possible clinical applications","volume":"10","author":"Wakiyama","year":"2021","journal-title":"Nanophotonics"},{"key":"10.1016\/j.biopha.2026.119793_bib5","unstructured":"2020 ClinicalTrials.gov, ASP-1929 photoimmunotherapy (PIT) study in recurrent head\/ neck cancer for patients who have failed at least two lines of therapy, https:\/\/Clinicaltrials.Gov\/Study\/NCT03769506 2026."},{"key":"10.1016\/j.biopha.2026.119793_bib6","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1039\/D2CB00094F","article-title":"Protein scaffolds: antibody alternatives for cancer diagnosis and therapy","volume":"3","author":"Luo","year":"2022","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.biopha.2026.119793_bib7","first-page":"271","article-title":"Site-specific conjugation of native antibody","volume":"3","author":"Sadiki","year":"2020","journal-title":"Antib. Ther."},{"key":"10.1016\/j.biopha.2026.119793_bib8","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3390\/ph18091316","article-title":"Alpha particle emitter radiolabeled antibodies in cancer therapy: current status, challenges, and future prospects","volume":"18","author":"Palangka","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2026.119793_bib9","first-page":"114","article-title":"Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate","volume":"7","author":"Ma","year":"2024","journal-title":"Antib. Ther."},{"key":"10.1016\/j.biopha.2026.119793_bib10","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1021\/bc300191z","article-title":"Gallium-67-labeled lactam bridge-cyclized alpha-MSH peptides with enhanced melanoma uptake and reduced renal uptake","volume":"23","author":"Guo","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.biopha.2026.119793_bib11","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3390\/molecules31020302","article-title":"Development of a peptide-based photoimmunotherapy drug targeting PD-L1","volume":"31","author":"Otani","year":"2026","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119793_bib12","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1124\/dmd.119.087809","article-title":"Effect of size on solid tumor disposition of protein therapeutics","volume":"47","author":"Li","year":"2019","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.biopha.2026.119793_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01287","article-title":"Antibody or antibody fragments: implications for molecular imaging and targeted therapy of solid tumors","volume":"8","author":"Xenaki","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119793_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117717","article-title":"Synthesis and biological evaluation of EGFR binding peptides for near-infrared photoimmunotherapy","volume":"105","author":"Otani","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119793_bib15","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1021\/acs.molpharmaceut.5b00132","article-title":"Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy","volume":"12","author":"Hanaoka","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119793_bib16","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3390\/ph18091419","article-title":"An overview of target membrane proteins for near-infrared photoimmunotherapy","volume":"18","author":"Suzuki","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2026.119793_bib17","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41467-021-21875-0","article-title":"Lasso-grafting of macrocyclic peptide pharmacophores yields multi-functional proteins","volume":"12","author":"Mihara","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119793_bib18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41551-022-00955-6","article-title":"Designing receptor agonists with enhanced pharmacokinetics by grafting macrocyclic peptides into fragment crystallizable regions","volume":"7","author":"Sakai","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.biopha.2026.119793_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/cplu.202400152","article-title":"Protein grafting techniques: from peptide epitopes to lasso-grafted neobiologics","volume":"89","author":"Imai","year":"2024","journal-title":"Chempluschem"},{"key":"10.1016\/j.biopha.2026.119793_bib20","doi-asserted-by":"crossref","first-page":"12213","DOI":"10.1021\/acs.chemrev.4c00422","article-title":"Selection of nucleotide-encoded mass libraries of macrocyclic peptides for inaccessible drug targets","volume":"124","author":"Colas","year":"2024","journal-title":"Chem. Rev."},{"key":"10.1016\/j.biopha.2026.119793_bib21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/19420862.2015.1113360","article-title":"Pharmacokinetic properties of IgG and various Fc fusion proteins in mice","volume":"8","author":"Unverdorben","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.biopha.2026.119793_bib22","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nbt1142","article-title":"Engineered antibody fragments and the rise of single domains","volume":"23","author":"Holliger","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119793_bib23","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.str.2022.07.008","article-title":"De novo Fc-based receptor dimerizers differentially modulate PlexinB1 function","volume":"30","author":"Sugano-Nakamura","year":"2022","journal-title":"Structure"},{"key":"10.1016\/j.biopha.2026.119793_bib24","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLOS Biol."},{"key":"10.1016\/j.biopha.2026.119793_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13550-023-01030-0","article-title":"Fc-engineered monoclonal antibodies to reduce off-target liver uptake","volume":"13","author":"Mangeat","year":"2023","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.biopha.2026.119793_bib26","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/s41598-019-38575-x","article-title":"Targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) expressing bladder cancer using combination photoimmunotherapy (PIT)","volume":"9","author":"Siddiqui","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119793_bib27","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.3390\/cancers13122992","article-title":"Photodynamic therapy: targeting cancer biomarkers for the treatment of cancers","volume":"13","author":"Wang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119793_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0960-9822(95)00006-6","article-title":"Immunodeficiency: Trapping the nude mouse gene","volume":"5","author":"Reth","year":"1995","journal-title":"Curr. Biol."},{"key":"10.1016\/j.biopha.2026.119793_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103501","article-title":"Near infrared photoimmunotherapy for cancers: a translational perspective","volume":"70","author":"Maruoka","year":"2021","journal-title":"EBioMedicine"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:42:23Z","timestamp":1787179343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226008292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"alternative-id":["S0753332226008292"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119793","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mirabody\u2013IR700: A novel EGFR-targeting platform for photoimmunotherapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119793","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119793"}}